The new drug has already passed Phase 1 safety trials in humans, making it a "strong candidate" for future PTSD treatments.

The lack of progress in development of drugs to effectively treat PTSD has become a 'crisis' and has created a significant shift in the Veterans Administration's clinical practice treatment guideline.

Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved No new PTSD drug approvals in the U.S. in nearly 25 years; large potential addressable ...

In people with traumatic brain injury, administering the psychedelic drug ibogaine seems to slow down brainwaves, which may ...

Veterans and experts testified on ibogaine's potential to treat PTSD and addiction, as lawmakers consider joining Texas in funding research.

(RTTNews) - Silo Pharma, Inc. (SILO) has announced a partnership with medical device company Resyca BV to conduct a drug-device study supporting the FDA IND submission for its lead asset SPC-15 ...

Hydrate Medical is expanding its services to offer ketamine therapy one day a week, according to a news release.

An experimental drug reverses PTSD-like symptoms in mice. The corresponding study was published in Signal Transduction and Targeted Therapy and may pave the way for a new treatment for PTSD. “This ...

Single-cell analyses revealed molecular profiles that can distinguish PTSD from depression, potentially leading to better ...

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025 ...

No new PTSD drug approvals in the U.S. in nearly 25 years; large potential addressable market for SPC-15 worldwide SARASOTA, FL, July 07, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (SILO) (“Silo ...